Introduction
Pyrazole derivatives are characterized by their biological and pharmacological activities as potential inhibitors of HIV-1 [1] , pesticides [2] , fungicides [3] , antihypertensive agents [4] and anticancer activity [5] . They are also important and useful precursors for the synthesis of other fused heterocyclic systems, among these pyrazolo [3,4-d] pyrimidine derivatives [6] , which have a considerable chemical and pharmacological importance as purine analogues [7] [8] [9] . In the literature, it was found that the replacement of 1H of pyrazole of pyrazolo [3,4-d] pyrimidine ring system by some other bioactive moieties drastically alters its pharmacological properties [10] . Also, the pyrazolo [3,4-b] pyridine derivatives represent important building blocks in both natural and synthetic bioactive compounds [11] . They show anxiolytic activity along with xanthine oxidase inhibitors, cholesterol formation inhibitor, and anti-Alzheimer [12] . Moreover, fused heterocyclic containing pyrazolopyridine systems have been described to be associated with several biological and medicinal activities [13] [14] [15] [16] . In the present work, some new 1-tosylpyrazolo [3,4-d] pyrimidine and 1-tosyl-pyrazolo [3,4-b] pyridine derivatives incorporating the tosyl moiety were synthesized to evaluate their potential cytotoxicity against epidermoid carcinoma of the larynx (Hep2).
Experimental

Materials and methods
All melting points (uncorrected) were determined on an electrothermal Gallenkamp melting point apparatus. The IR spectra were recorded in KBr disks on a Thermo Scientific Nicolet iS 50 FT-IR spectrometer (not all frequencies are reported). The NMR spectra were acquired using a Bruker WP 300 spectrometer at 300 MHz using TMS as an internal standard and DMSOd6 as solvent. The mass spectra were performed using a LC-MS (Shimadzu-Mass spectrometer) at 70 eV. Elemental analyses were carried out at the Microanalytical Unit, Cairo University, Giza, Egypt; the results were in satisfactory agreement with the calculated values.
5-amino-1-tosyl-1H-pyrazole-3,4-dicarbonitrile (2)
To a cold solution of p-toluenesulfonyl hydrazide (0.05 mol, 9.3 g) in 50 ml ethanol, tetracyanoethylene (0.05 mol, 6.4 g) was added. 
4,5,6,7-tetrahydro-4,6-dithioxo-1-tosyl-1H-pyrazolo[3,4-d]pyrimidine-3-carbonitrile (3)
To a stirred suspension of compound 2 (2 mmol, 0.57 g) in pyridine (20 ml), carbon disulfide (4 mmol, 0.3 ml) was added dropwise. The reaction mixture was then heated on water bath for 12 hrs. The reaction mixture was cooled at room temperature, then poured into ice cold water, and neutralized with hydrochloric acid. The precipitated product was filtered off, washed and recrystallized from EtOH-DMF mixture (1:1) to afford the corresponding product 3 as dark green crystals. 
4-Amino
A mixture of compound 2 (2 mmol, 0.57 g) and thiourea (2 mmol, 0.16 g) was heated together in oil bath at 180-185°C for 2 hrs. After cooling, the resulting solid was dissolved in dilute sodium hydroxide and then acidified with dil. HCl to give the crude product 5. The solid product that formed was filtered off, dried and then recrystallized from EtOH to furnish 5 as dark yellow crystals.
Yield 65%; mp (°C); > 300; IR ( V cm 
4,5-Diamino-6-thioxo-1-tosyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-d]pyrimidine-3-carbonitrile (6)
A mixture of compound 2 (2 mmol, 0.57 g) and thiosemicarbazide (2 mmol, 0.19 g) was fused in oil bath at 180-185°C for 3 hrs under dry conditions. The fused mixture was heated in ethanol (15 ml) and the precipitate that formed on cooling was collected by filtration, dried and recrystallized from EtOH:DMF mixture (1:1) to furnish compound 6 as brown crystals. 
4-Oxo-1-tosyl-4,5-dihydro-1H-pyrazolo[3,4-d] pyrimidine-3-carbonitrile (7)
A suspension of compound 2 (2 mmol, 0.57 g) in excess of formic acid (10 ml) was refluxed on sand bath for 6 hrs. After cooling, the mixture was diluted by cooled water (10 ml) and the precipitate that formed was filtered off, dried and purified by recrystallization from EtOH to give 7 as yellowish brown powder. 
4-Amino-1-tosyl-1H-pyrazolo[3,4-d]pyrimidine-3-carbonitrile (8)
A mixture of pyrazole 2 (2 mmol, 0.57 g) and formamide (10 ml) in DMF (10 ml) was heated under reflux for 12 hrs. The reaction mixture was allowed to cool at room temperature and poured onto 200 ml ice-cooled water. 
Ethyl N-3,4-dicyano-1-tosyl-1H-pyrazol-5-yl formimidate (9)
To a mixture of triethyl orthoformate (5 mmol, 0.75 ml) and acetic anhydride (20 ml), the pyrazole 2 (5 mmol, 1.44 g) was added. The reaction mixture was refluxed for 5 hrs and the solvent was removed under reduced pressure. The separated solid was recrystallized from ethanol to afford 9 as a yellow powder. 
5-Amino-4-imino-1-tosyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidine-3-carbonitrile (10)
To a solution of compound 9 (2 mmol, 0.68 g) in absolute ethanol (50 ml), hydrazine hydrate (4 mmol, 0.2 ml) was added. The reaction mixture was refluxed for 4 hrs, concentrated and cooled. The solid product that separated out was filtered off and recrystallized from EtOH to yield 10 as a yellow powder. 
5-Acetyl-4-amino-6-hydroxy-1-tosyl-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile (12)
A mixture of compound 2 (4 mmol, 1.36 g), potassium carbonate (6 mmol, 0.83 g) and ethyl acetoacetate (4 mmol, 0.52 ml) in 15 ml DMF was heated under reflux for 12 hrs. The reaction mixture was allowed to cool at room temperature, poured into ice-cooled water and then neutralized by drops of dilute 11. 4,6-diamino-1-tosyl-1H-pyrazolo [3,4-b] pyridine-3,5-dicarbonitrile (13) A mixture of compound 2 (4 mmol, 1.36 g) and malononitrile (4 mmol, 0.27 g) in 15 ml DMF containing few drops of piperidine was refluxed for 12 hrs. The reaction mixture was allowed to cool to room temperature, diluted with cold water and then neutralized by few drops of dilute HCl. The resulting solid was filtered off, washed several times with cold water, dried and then recrystallized from EtOH:DMF mixture (1:1) to afford 13 as brown crystals.
Yield 67%; mp (°C); > 300; IR ( V cm 
2.2.
In vitro antitumor activity
Cell line
Epidermoid carcinoma (larynx) Hep2 was obtained from ATCC via a holding company for biological products and vaccines (VACSERA), Cairo, Egypt. 5-Fluorouracil was used as a standard anticancer drug for comparison.
Chemical reagents
The reagents were RPMI-1640 medium, MTT, DMSO and 5-fluorouracil (Sigma Co., St. Louis, USA), and fetal bovine serum (GIBCO, UK).
MTT assay [18]
The cell line mentioned above was utilized to determine the inhibitory effects of compounds on cell growth utilizing the MTT test. This colorimetric test is based on the transformation of the yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) to a purple formazan derivative by mitochondrial succinate dehydrogenase in practical cells. Hep2 was refined in RPMI-1640 medium with 10% fetal bovine serum. The anti-toxins included were 100 units/ml penicillin and 100 μg/ml streptomycin at 37°C in a 5% CO2 incubator. The cell line was seeded in a 96-well plate at a density of 1 × 10 4 cells/ well [19] at 37°C for 48 hours under 5% CO2. After incubation the cells were treated with distinctive concentration of compounds and incubated for 24 hours. After 24 hours of medication treatment, 20 μl of MTT solution at 5 mg/ml was added and incubated for 4 hours. Dimethyl sulfoxide (DMSO) in volume of 100 μl is added into each well to dissolve the purple formazan formed. The colorimetric test is measured and recorded at the absorbance of 570 nm utilizing a plate reader (EXL 800, USA). The relative cell viability in percentage was ascertained as: (A570 of treated samples/A570 of untreated sample) × 100.
Results and discussion
Chemistry
The key starting material 5-amino-1-tosyl-1H-pyrazole-3,4-dicarbonitrile (2) was synthesized in 80% yield by refluxing p-toluenesulfonyl hydrazide (1) with tetracyanoethylene in absolute ethanol [17] . The ease synthesis and expected biological activity of the starting compound prompted us to prepare some 3-cyano-1-tosyl-pyrazolo [3,4- H NMR spectra of 4 revealed the presence of singlet signal at 2.35 ppm for methyl protons (CH3), and two singlet signals at 10.25 and 12.45 ppm of two NH protons, in addition to the aromatic protons as multiplet (7H) and doublet (2H) in the range 6.90-7.65 ppm. The mass spectrum showed the molecular ion peak at m/z = 422 corresponding to the molecular weight of its chemical formula C19H14N6O2S2.
Fusion of pyrazole 2 with thiourea furnished one product on TLC, which identified as 4-amino-6-thioxo-1-tosyl-6,7-dihydro-1H-pyrazolo [3,4- H NMR revealed two singlet signals at 2.35 and 2.50 ppm for six protons of two methyl groups (2CH3), singlet signal at 6.02 ppm referring to the (NH2) protons, two doublet signals at 7.35 and 7.75 ppm for para-disubstituted benzene ring protons, and singlet signal at 11.55 ppm corresponding to (OH) proton. The mass spectrum showed the molecular ion peak at m/z = 371 corresponding to the molecular weight of the molecular formula C16H13N5O4S.
Heating of compound 2 with malononitrile in refluxing DMF containing piperidine produces a sole product that identified as 4,6-diamino-1-tosyl-1H-pyrazolo [3,4-b] pyridine-3,5-dicarbonitrile 13, in 67% isolated yield. Presumably, ionized malononitrile attacks the cyano group in compound 2 before the amino group of the latter attacks one of the malononitrile cyano groups resulting in ring formation. The IR spectrum showed absorption peaks at 3410, 3335 and 3245 cm 
3.2.
In vitro antitumor activity
The antitumor activity of the synthesized compounds were evaluated against human laryngeal epidermoid carcinoma cell line (Hep2) using the MTT assay method. The results acquired in Table 1 demonstrated that compounds 3 (IC50 36.9 μM) and 4 (IC50 21.3 μM) have the highly significant effect compared to the standard anticancer drug 5-fluorouracil (IC50 41.5 μM). This may be because of the presence of such NH-C-S moiety in addition to the N-tosyl-pyrazolo-pyrimidine moiety in the two compounds. The other compounds showed low impact against epidermoid carcinoma (Hep2). 
